- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07788521
Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal
This study is a 4-visit, multi-site, prospective, controlled, randomized, single-masked (subjects), two-arm parallel group, bilateral, dispensing clinical trial to compare the performance of the Test lens to the Control lens in terms of safety and efficacy.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 1-800-843-2020
- E-post: tkarkkai@its.jnj.com
Studiesteder
-
-
Florida
-
Longwood, Florida, Forente stater, 32779
- Fullført
- Pearson Research Center PA
-
-
Georgia
-
Roswell, Georgia, Forente stater, 30076
- Aktiv, ikke rekrutterende
- VisualEyes
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63144
- Aktiv, ikke rekrutterende
- The Koetting Associates
-
-
New York
-
Jamestown, New York, Forente stater, 14701
- Rekruttering
- Spectrum Eyecare
-
Manhattan, New York, Forente stater, 10022
- Rekruttering
- Center for Ophthalmic and Vision Research/Eye Associates of New York
-
Vestal, New York, Forente stater, 13850
- Aktiv, ikke rekrutterende
- Sacco Eye Group
-
-
Rhode Island
-
Warwick, Rhode Island, Forente stater, 02888
- Aktiv, ikke rekrutterende
- Dr. David W. Ferris & Associates
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38119
- Fullført
- Total Eye Care
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Paradigm Research Center, LLC
-
Tyler, Texas, Forente stater, 75703
- Aktiv, ikke rekrutterende
- Tyler Eye Associates
-
-
Virginia
-
Salem, Virginia, Forente stater, 24153
- Rekruttering
- Botetourt Eyecare, LLC
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Be at least 40 years of age and not greater than 70 years of age at the time of consent.
- Own a wearable pair of spectacles if required for their distance vision.
- Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 30 days or more duration).
- Either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".
- The subject's distance spherical equivalent refraction (vertex corrected if ≥-4.25 D) must be in the range of -1.50 D to -5.50 D in each eye.
- The subject's refractive cylinder must be ≤0.75 D in each eye.
- The subject's ADD power must be in the range of +0.75 D to +2.50 D.
- The subject must have distance best corrected visual acuity of 0.0 logMAR (20/20 Snellen, 5.0 on the China standard 5-point logMAR visual acuity scale) or better in each eye.
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Be currently pregnant or lactating.
- Have any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
- Have been diagnosed with diabetes.
- Have any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
- Have any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cataract surgery, retinal surgery, etc.).
- Have a history of amblyopia, strabismus or binocular vision abnormality.
- Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids.
- Use of any ocular medication.
- Have a history of herpetic keratitis.
- Have a history of irregular cornea.
- Have a history of pathological dry eye.
- Have a history of glaucoma or glaucoma suspect.
- Have a history of any retinal disease/condition that may interfere with any of the study assessments or are not stable and have potential to progress during the study.
- Have participated in any contact lens or lens care product clinical trial within 15 days prior to study enrollment.
- Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild, sibling of the employee or their spouse) of the clinical site.
- Have any known hypersensitivity or allergic reaction to sodium fluorescein.
- Have Grade 3 or greater palpebral conjunctival observations or Grade 2 or greater slit lamp findings (e.g. corneal edema, corneal vascularization, corneal staining, bulbar injection, etc.) on the ISO 11980 classification scale, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
- Have any current ocular infection or inflammation.
- Have intraocular pressure in one or both eyes >21mmHg
- Have signs of any retinal disease/conditions that may interfere with any of the study assessments or are not stable and have potential to progress during the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Senofilcon A
Eligible subjects will be randomized to the Senofilcon A Lens for the duration of the study. |
ACUVUE® Oasys MAX 1-Day Multifocal |
|
Aktiv komparator: Nelfilcon A
Eligible subjects will be randomized to the Nelfilcon A Lens for the duration of the study. |
DAILIES® AquaComfort Plus® Multifocal |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence rate of study-lens related (i.e. related and possibly related) ocular adverse events.
Tidsramme: Up to 1-month follow-up
|
Up to 1-month follow-up
|
|
|
Mean binocular HLHC distance Visual Acuity
Tidsramme: At 1-week follow-up
|
Mean binocular HLHC VA at distance (4m) |
At 1-week follow-up
|
|
Mean binocular HLHC Intermediate Visual Acuity
Tidsramme: At 1-week follow-up
|
Mean binocular HLHC VA at Intermediate (64cm) |
At 1-week follow-up
|
|
Mean binocular HLHC Near Visual Acuity
Tidsramme: At 1-week follow-up
|
Mean binocular HLHC VA at Near (40cm) |
At 1-week follow-up
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean binocular HLHC distance Visual Acuity
Tidsramme: At 1-month follow-up
|
Mean binocular HLHC VA at distance (4m) |
At 1-month follow-up
|
|
Mean binocular HLHC Intermediate Visual Acuity
Tidsramme: At 1-month follow-up
|
Mean binocular HLHC VA at Intermediate (64cm) |
At 1-month follow-up
|
|
Mean binocular HLHC Near Visual Acuity
Tidsramme: At 1-month follow-up
|
Mean binocular HLHC VA at Near (40cm) |
At 1-month follow-up
|
|
Incidence rate of Slit Lamp Findings (SLF)
Tidsramme: Up to 1-month follow-up
|
Slit lamp findings will be assessed for each eye at all study visits (scheduled and unscheduled) by grade. SLFs will be evaluated and graded using the ISO 11980 Grading scale from 0 to 4, where Grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e., Grade 1 = trace, Grade 2 = mild, Grade 3 = moderate and Grade 4 = severe). |
Up to 1-month follow-up
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Johnson & Johnson Vision Care, Inc. Clinical Trial, Johnson & Johnson Vision Care, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CR-6560
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .